Baylor College of Medicine: A Potentially More Effective Treatment for HER2 Mutant Metastatic Breast Cancer
June 25, 2022
June 25, 2022
HOUSTON, Texas, June 25 (TNSjou) -- The Baylor College of Medicine issued the following news:
Breast cancers with HER2 mutations respond to the drug neratinib, but the responses are variable and often not durable. Looking to better understand the underlying cause of this variation, a team led by researchers at Baylor College of Medicine investigated whether different HER2 mutations drove different responses to therapy. They were able to identify a mutation that conferred therapeutic . . .
Breast cancers with HER2 mutations respond to the drug neratinib, but the responses are variable and often not durable. Looking to better understand the underlying cause of this variation, a team led by researchers at Baylor College of Medicine investigated whether different HER2 mutations drove different responses to therapy. They were able to identify a mutation that conferred therapeutic . . .